BeOne Medicines AG (HKG:6160)
Hong Kong · Delayed Price · Currency is HKD 163.00
+3.30 (2.07%)
Jun 10, 2026, 4:09 PM HKT
BeOne Medicines AG Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Operating Revenue | 38,929 | 36,945 | 27,587 | 15,528 | 9,766 | 7,472 |
Other Revenue | 420.55 | 426.46 | 224.05 | 1,907 | - | - |
| 39,349 | 37,371 | 27,811 | 17,435 | 9,766 | 7,472 | |
Revenue Growth (YoY) | 29.86% | 34.37% | 59.51% | 78.53% | 30.69% | 270.56% |
Cost of Revenue | 4,631 | 4,676 | 4,336 | 2,694 | 1,976 | 1,048 |
Gross Profit | 34,718 | 32,695 | 23,475 | 14,741 | 7,790 | 6,425 |
Selling, General & Admin | 14,913 | 14,559 | 13,365 | 10,693 | 8,819 | 6,290 |
Research & Development | 15,111 | 15,009 | 14,257 | 12,612 | 11,315 | 9,270 |
Amortization of Goodwill & Intangibles | - | - | - | - | - | 4.76 |
Operating Expenses | 30,003 | 29,568 | 27,622 | 23,305 | 20,134 | 15,565 |
Operating Income | 4,715 | 3,127 | -4,147 | -8,564 | -12,344 | -9,140 |
Interest Expense | -401.66 | -407.31 | -159.16 | -30.94 | -131.77 | -179.2 |
Interest & Investment Income | 565.9 | 493.14 | 508.32 | 555.74 | 493.74 | 79.1 |
Earnings From Equity Investments | -103.34 | -104.79 | -75 | -55.71 | -25.4 | -11.41 |
Other Non Operating Income (Expenses) | 15.11 | 223.56 | 47.74 | -285.74 | -1,346 | 52.82 |
EBT Excluding Unusual Items | 4,791 | 3,332 | -3,825 | -8,381 | -13,353 | -9,198 |
Gain (Loss) on Sale of Investments | -395.33 | -416.4 | -64.98 | -48.74 | -172.69 | 59.63 |
Gain (Loss) on Sale of Assets | 0.02 | - | - | - | - | - |
Other Unusual Items | - | - | - | 2,573 | - | - |
Pretax Income | 4,538 | 2,916 | -3,890 | -5,856 | -13,526 | -9,139 |
Income Tax Expense | 856.54 | 908.72 | 815.93 | 396.18 | 295.05 | 122.15 |
Earnings From Continuing Operations | 3,681 | 2,007 | -4,706 | -6,252 | -13,821 | -9,261 |
Net Income | 3,681 | 2,007 | -4,706 | -6,252 | -13,821 | -9,261 |
Net Income to Common | 3,681 | 2,007 | -4,706 | -6,252 | -13,821 | -9,261 |
Shares Outstanding (Basic) | 111 | 109 | 105 | 104 | 103 | 93 |
Shares Outstanding (Diluted) | 117 | 113 | 105 | 104 | 103 | 93 |
Shares Change (YoY) | 10.10% | 7.75% | 0.86% | 1.22% | 11.15% | 11.16% |
EPS (Basic) | 33.18 | 18.40 | -44.70 | -59.89 | -134.01 | -99.81 |
EPS (Diluted) | 31.16 | 17.28 | -44.70 | -59.92 | -134.01 | -99.81 |
Free Cash Flow | 8,132 | 6,587 | -4,622 | -12,192 | -12,567 | -9,921 |
Free Cash Flow Per Share | 69.71 | 58.06 | -43.90 | -116.79 | -121.85 | -106.92 |
Gross Margin | 88.23% | 87.49% | 84.41% | 84.55% | 79.77% | 85.98% |
Operating Margin | 11.98% | 8.37% | -14.91% | -49.12% | -126.40% | -122.31% |
Profit Margin | 9.36% | 5.37% | -16.92% | -35.86% | -141.52% | -123.93% |
Free Cash Flow Margin | 20.67% | 17.63% | -16.62% | -69.93% | -128.68% | -132.76% |
EBITDA | 5,666 | 4,048 | -2,928 | -7,969 | -11,909 | -8,851 |
EBITDA Margin | 14.40% | 10.83% | -10.53% | -45.71% | -121.94% | -118.44% |
D&A For EBITDA | 950.5 | 921.04 | 1,219 | 595.18 | 434.89 | 288.99 |
EBIT | 4,715 | 3,127 | -4,147 | -8,564 | -12,344 | -9,140 |
EBIT Margin | 11.98% | 8.37% | -14.91% | -49.12% | -126.40% | -122.31% |
Effective Tax Rate | 18.88% | 31.17% | - | - | - | - |
Revenue as Reported | 36,853 | 37,371 | 27,811 | 17,435 | 9,766 | 7,472 |